Rolf Thieringer

Statistics

Publications

Citations

4.4K

H-Index

Active since

1988

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Université Laval

Rockefeller University

Icahn School of Medicine at Mount Sinai

Rosetta Stone (United States)

Rolf Thieringer is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in life sciences, pharmacology, and 11 beta-hydroxysteroid dehydrogenase.

Publications per year

1988–2012

Publications

An integrative genomics approach to infer causal associations between gene expression and disease

Eric E. Schadt, John R. Lamb, Xia Yang et al. · Nature Genetics · 2005 · 1.1K citations · Full text

Life Sciences, Bioinformatics, Genetics +16

11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice

Anne Hermanowski‐Vosatka, James M. Balkovec, Kang Cheng et al. · The Journal of Experimental Medicine · 2005 · 363 citations · Full text

Life Sciences, Endocrinology, Pharmacology +17

An integrative genomics approach to the reconstruction of gene networks in segregating populations

Jun Zhu, Pek Yee Lum, John R. Lamb et al. · Cytogenetic and Genome Research · 2004 · 227 citations

Life Sciences, Bioinformatics, Genetics +13

Peroxisome Proliferator-activated Receptor-γ Ligands Inhibit Adipocyte 11β-Hydroxysteroid Dehydrogenase Type 1 Expression and Activity

Joel P. Berger, Michael Tanen, Alex Elbrecht et al. · Journal of Biological Chemistry · 2001 · 207 citations · Full text

Life Sciences, Endocrinology, Pharmacology +17

Activation of Peroxisome Proliferator-Activated Receptor γ Does Not Inhibit IL-6 or TNF-α Responses of Macrophages to Lipopolysaccharide In Vitro or In Vivo

Rolf Thieringer, Judy Fenyk‐Melody, Cheryl B. Le Grand et al. · The Journal of Immunology · 2000 · 194 citations · Full text

Life Sciences, Immunology, Pharmacology +17

1–5 of 39